Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto J Montero

Showing results (41-50 of 132) with videos related to

Pageof 14
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|March 31, 2026
CLO26-094: Genomic Risk Distribution, Adjuvant Chemotherapy Trends, and Survival Outcomes in Women With pT1N0, Grade 1-2, ER/PR-Positive, LVI-Negative Breast CancerNickolas Stabellini, Maya Lubarsky, Amanda L Amin, et al.
Current Medical Research and Opinion|January 30, 2016
Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patientsVakaramoko Diaby, Askal A Ali, Georges Adunlin, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|March 1, 2018
Androgen Receptors in Resected Ductal Carcinoma In Situ of Breast: Novel Insights With Possible Implications for Testing and Targeted Endocrine Chemoprevention TrialsOlaronke Oshilaja, Laila Nomani, Benjamin C Calhoun, et al.
Cancer Biology & Therapy|April 1, 2008
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature reviewVinay Gudena, Nitin Verma, Ginell Post, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2026
CLO26-094: Genomic Risk Distribution, Adjuvant Chemotherapy Trends, and Survival Outcomes in Women With pT1N0, Grade 1-2, ER/PR-Positive, LVI-Negative Breast CancerNickolas Stabellini, Maya Lubarsky, Amanda L Amin, et al.
Cancer Medicine|September 28, 2023
Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysisNickolas Stabellini, Lifen Cao, Christopher W Towe, et al.
Cancer Causes & Control : CCC|December 22, 2009
Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor statusJoan E Cunningham, Alberto J Montero, Elizabeth Garrett-Mayer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2012
Myeloid-derived suppressor cells in cancer patients: a clinical perspectiveAlberto J Montero, Claudia Marcela Diaz-Montero, Christos E Kyriakopoulos, et al.
Seminars in Nuclear Medicine|June 5, 2021
PET/CT Variants and Pitfalls in Breast CancersElias George Kikano, Stefanie Avril, Holly Marshall, et al.
Expert Review of Anticancer Therapy|June 7, 2008
Upper gastrointestinal tumors: current status and future perspectivesYixing Jiang, Eric T Kimchi, Alberto J Montero, et al.
Pageof 14

Showing results (41-50 of 132) with videos related to

Sort By:
Pageof 14
Journal of the National Comprehensive Cancer Network : JNCCN|March 31, 2026
CLO26-094: Genomic Risk Distribution, Adjuvant Chemotherapy Trends, and Survival Outcomes in Women With pT1N0, Grade 1-2, ER/PR-Positive, LVI-Negative Breast CancerNickolas Stabellini, Maya Lubarsky, Amanda L Amin, et al.
Current Medical Research and Opinion|January 30, 2016
Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patientsVakaramoko Diaby, Askal A Ali, Georges Adunlin, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|March 1, 2018
Androgen Receptors in Resected Ductal Carcinoma In Situ of Breast: Novel Insights With Possible Implications for Testing and Targeted Endocrine Chemoprevention TrialsOlaronke Oshilaja, Laila Nomani, Benjamin C Calhoun, et al.
Cancer Biology & Therapy|April 1, 2008
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature reviewVinay Gudena, Nitin Verma, Ginell Post, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2026
CLO26-094: Genomic Risk Distribution, Adjuvant Chemotherapy Trends, and Survival Outcomes in Women With pT1N0, Grade 1-2, ER/PR-Positive, LVI-Negative Breast CancerNickolas Stabellini, Maya Lubarsky, Amanda L Amin, et al.
Cancer Medicine|September 28, 2023
Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysisNickolas Stabellini, Lifen Cao, Christopher W Towe, et al.
Cancer Causes & Control : CCC|December 22, 2009
Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor statusJoan E Cunningham, Alberto J Montero, Elizabeth Garrett-Mayer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2012
Myeloid-derived suppressor cells in cancer patients: a clinical perspectiveAlberto J Montero, Claudia Marcela Diaz-Montero, Christos E Kyriakopoulos, et al.
Seminars in Nuclear Medicine|June 5, 2021
PET/CT Variants and Pitfalls in Breast CancersElias George Kikano, Stefanie Avril, Holly Marshall, et al.
Expert Review of Anticancer Therapy|June 7, 2008
Upper gastrointestinal tumors: current status and future perspectivesYixing Jiang, Eric T Kimchi, Alberto J Montero, et al.
Pageof 14